Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026)

Catalyst Pharmaceuticals has reported Finished Goods for 4 years, with the latest figure at $15.3 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 88.21% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $15.3 million (up 88.21% YoY), and the FY2025 full-year result was $16.2 million, up 68.7% from the prior year.
• Finished Goods for Q1 2026 stood at $15.3 million, down from $16.2 million in the prior quarter.
• The five-year high for Finished Goods was $16.2 million in Q4 2025, with the low at $8.1 million in Q1 2025.
• Historically, Finished Goods has averaged $10.6 million across 4 years, with a median of $9.2 million in 2024.
• Annual changes were most pronounced in 2025 — Finished Goods fell 3.29% — and 2026, when it jumped 88.21%.
• Catalyst Pharmaceuticals' Finished Goods stood at $9.2 million in 2023, then grew by 4.55% to $9.6 million in 2024, then soared by 68.7% to $16.2 million in 2025, then slipped by 5.43% to $15.3 million in 2026.
• The last three Finished Goods figures came in at $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.